Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q4VC12
UPID:
MSS51_HUMAN
Alternative names:
Zinc finger MYND domain-containing protein 17
Alternative UPACC:
Q4VC12; A6NGH6; Q2VP95; Q5F2H5; Q7Z3M9; Q8N8G0
Background:
The Putative protein MSS51 homolog, mitochondrial, also known as Zinc finger MYND domain-containing protein 17, plays a crucial role in mitochondrial function. Its involvement in cellular energy metabolism underscores its importance in maintaining cellular health and function.
Therapeutic significance:
Understanding the role of Putative protein MSS51 homolog, mitochondrial could open doors to potential therapeutic strategies. Its pivotal role in energy metabolism makes it a promising target for addressing mitochondrial disorders.